Closing the Bundibugyo Ebola Preparedness Gap

The modern Ebola vaccine field was shaped by the 2014–2016 West Africa epidemic and subsequent DRC outbreaks. The most important precedent is the development and deployment of rVSV-ZEBOV, a recombinant vesicular stomatitis virus vector expressing the Zaire ebolavirus glycoprotein. This vaccine demonstrated effectiveness in ring-vaccination studies and became a central tool in Zaire ebolavirus outbreak response. Additional platforms, including adenoviral vectors and heterologous prime-boost regimens, have also contributed to the evidence base for filovirus vaccination.

An historical lesson sums up the current challenges: vaccine preparedness must be species-specific and outbreak ready. Zaire ebolavirus vaccines were able to move rapidly because candidate products, clinical protocols, manufacturing processes, regulatory packages, and ethical frameworks had been advanced before major outbreaks. By contrast, Bundibugyo ebolavirus has received less sustained investment, leaving the 2026 response dependent on accelerated development of candidates that are scientifically promising but not yet licensed.

CEPI has fast-tracked three candidate vaccines against Bundibugyo ebolavirus under its emergency response framework. The decision reflects the absence of any licensed vaccine against Bundibugyo virus and the urgent need to establish a clinical-stage candidate that could be deployed under emergency use authorization during the ongoing outbreak. CEPI stated that the 100 Days Mission framework would guide its acceleration approach, with the aim of generating safety and immunogenicity data as rapidly as possible. To support this initiative, Africa CDC and WHO have coordinated a continental strategy to contain the Bundibugyo ebolavirus outbreak.  The joint continental response plan coordinates surveillance, response capacity, and preparedness activities across African Union member states. The vaccine-development response focuses on translating prior filovirus platform experience to Bundibugyo ebolavirus. Candidate selection is driven by four criteria: biological plausibility of antigen design, platform-specific speed and manufacturability, prior human safety experience, and ability to support emergency clinical evaluation. WHO advisory groups have recommended that candidate vaccines and therapeutics be used within clinical trials wherever feasible, because the outbreak presents both urgent need and a rare opportunity to generate interpretable evidence.

In addition to the three fast-tracked candidates, CEPI also announced, on August 27, 2026, having committed up to $16.5 million to push the Egyptian drugmaker Minapharm’s Bundibugyo vaccine candidate into the clinic. Minapharm is developing a vaccine candidate based on the modified vaccinia Ankara platform. A similar technology has provided long-term immunity against Zaire ebolavirus in earlier studies. CEPI funding positions Minapharm to take its Bundibugyo vaccine candidate through preclinical tests and into an early-stage safety and immunogenicity human trial.  

Beyond this Vaccinia Ankara candidate, the three CEPI-fast-tracked vaccine candidates are described below. 

The rVSV platform is the most directly validated Ebola vaccine platform because it underlies the licensed Zaire ebolavirus vaccine. For Bundibugyo, the concept is to engineer a replication-competent or attenuated rVSV vector to express Bundibugyo glycoprotein, thereby inducing humoral and cellular immune responses against the relevant species. IAIV is major sponsor for this candidate, as it has extensive rVSV filovirus platform experience and related programs for Sudan virus. The strategic advantage is platform precedent: single-dose administration, prior outbreak-use experience, and a regulatory analogy to rVSV-ZEBOV. The key uncertainties for this approach relate to the speed of candidate manufacturing, clinical readiness, reactogenicity profile, correlates of protection, and whether immune bridging can support accelerated review.

Adenoviral vectors provide an alternative approach with substantial human experience from Ebola, COVID-19, and other vaccine programs. The University of Oxford is advancing a ChAdOx1-based Bundibugyo candidate. ChAdOx1 is a non-replicating chimpanzee adenovirus vector that can be rapidly adapted to encode a target antigen. Related chimpanzee adenovirus platforms are also being used in Sudan ebolavirus vaccine development, including Sabin Vaccine Institute’s cAd3 program, which provides relevant platform experience even though the antigen target differs. Adenoviral vectors may be attractive for scalable manufacturing and known clinical operations, but they may require careful evaluation of dose, durability, pre-existing vector immunity, safety in special populations, and protection against severe disease.

mRNA vaccines offer the fastest antigen-to-clinic development pathway when sequence, formulation, and manufacturing capacity are available. Moderna is developing an mRNA vaccine candidate against Bundibugyo ebolavirus. The platform’s advantages include rapid design, modular manufacturing, and the ability to encode stabilized or optimized glycoprotein antigens. Important limitations include cold-chain complexity, limited filovirus efficacy precedent relative to rVSV-ZEBOV, uncertainty about the immune response needed for rapid post-exposure or ring-vaccination protection, and the need for safety and immunogenicity data in outbreak-relevant populations.

Manufacturing strategy is central to the scientific and ethical value of Bundibugyo vaccine development. A vaccine that demonstrates acceptable safety and immunogenicity during an outbreak must also be available in sufficient quantity, with release testing, cold-chain management, labeling, indemnification, import authorization, and field deployment protocols already planned. The Oxford/SII program illustrates a rapid manufacturing model in which investigational doses and a larger stockpile were produced before definitive efficacy data were available. The rVSV program illustrates a different challenge: strong platform precedent and animal evidence must be translated into GMP production, assay qualification, and clinical material availability. The mRNA program highlights the potential for rapid platform adaptation but requires a supply-chain and cold-chain plan suitable for affected districts.

Access strategy should be defined before efficacy results are available. Priority-use scenarios include ring vaccination around confirmed cases, vaccination of contacts and contacts of contacts, pre-exposure protection of frontline health workers and burial teams, and targeted vaccination in zones with sustained transmission. Funders and sponsors should define allocation principles, pricing, liability, data-sharing commitments, pharmacovigilance obligations, and transition from emergency supply to a durable stockpile.

Regulatory strategy for Bundibugyo vaccines should be designed around emergency evidence generation, platform-based inference, and international alignment. A conventional placebo-controlled efficacy trial may be difficult if case numbers decline, if ring vaccination is ethically preferred, or if insecurity prevents consistent follow-up. Therefore, developers and regulators should pre-specify multiple evidence pathways: randomized ring-vaccination trials where feasible, individually randomized trials among contacts or high-risk workers, adaptive platform trials, immunogenicity studies with immune-bridging to nonhuman-primate protection, and emergency-use or compassionate-use mechanisms when benefits plausibly outweigh risks.

The most credible near-term regulatory approach will likely rely on a staged pathway. First, obtain national authorization and ethics approval for outbreak clinical trials in DRC and Uganda, with WHO coordination and independent data monitoring. Second, generate phase 1/2 safety and immunogenicity data as rapidly as possible, including harmonized assays for Bundibugyo glycoprotein binding and neutralizing antibodies. Third, collect efficacy data opportunistically during ring or targeted vaccination if transmission permits. Fourth, use platform comparability, animal-rule-like evidence where applicable, and immune-bridging to support emergency use listing, conditional authorization, or expanded access. Fifth, convert emergency evidence into a full licensure package through larger safety databases, manufacturing consistency data, pharmacovigilance, and post-authorization effectiveness studies.

Outbreak vaccine trials must be operationally simple, ethically transparent, and integrated with response activities. Trial designs should prioritize high-risk contacts, contacts of contacts, frontline health workers, burial teams, laboratory staff, and communities with active transmission. Community engagement must precede enrollment, especially where distrust, misinformation, and insecurity are present. Cold-chain requirements, adverse-event monitoring, pregnancy considerations, pediatric inclusion, informed consent, and data capture must be planned before doses arrive. Importantly, vaccination should never replace surveillance, isolation, care, or infection prevention and control; it should reinforce them.

The 2026 outbreak demonstrates that Ebola preparedness cannot be limited to Zaire ebolavirus. A resilient portfolio should include species-specific candidates for Bundibugyo, Sudan, and other pathogenic filoviruses; validated diagnostics; monoclonal antibody and antiviral options; regional manufacturing capacity; pre-approved clinical protocols; and standing community-engagement partnerships. The outbreak also supports a portfolio approach rather than reliance on a single platform. In the current portfolio, rVSV may be most mature for Ebola outbreak use, adenoviral vectors may provide robust scalability and complementary immunology, and mRNA may offer speed and antigenic flexibility. Coordinated investment is needed to move each from reactive emergency development to proactive readiness.